Literaturhinweise
- Global burden of peripheral artery disease and its risk factors, 1990 2019: a systematic analysis for the Global Burden of Disease Study 2019Kim, Min Seo et al.
The Lancet Global Health, Volume 11, Issue 10, e1553 - e1565
- Fujihara M, Takahara M, Sasaki S, et al. Angiographic Dissection Patterns and Patency Outcomes After Balloon Angioplasty for Superficial Femoral Artery Disease. J Endovasc Ther. 2017;24(3):367-375. doi:10.1177/1526602817698634
- Jaff MR, Rosenfield K, Scheinert D, et al. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. Am Heart J. 2015;169(4):479-485. doi:10.1016/j.ahj.2014.11.016
- Krankenberg H, Tübler T, Ingwersen M, et al. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation. 2015;132(23):2230-2236. doi:10.1161/CIRCULATIONAHA.115.017364
- Feldman DN, Armstrong EJ, Aronow HD, et al. SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv. 2018;92(1):124-140. doi:10.1002/ccd.27635
- Wu Z, Huang Q, Pu H, et al. Atherectomy Combined with Balloon Angioplasty versus Balloon Angioplasty Alone for de Novo Femoropopliteal Arterial Diseases: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021;62(1):65-73. doi:10.1016/j.ejvs.2021.02.012
- Fan W, Lu S, Tan J, et al. Midterm Results of Drug-Coated Balloon Alone or Combined with Rotarex Thrombectomy Device for Treatment of Subacute Femoropopliteal Artery Thrombotic Occlusion. Ann Vasc Surg. 2023;92:240-248. doi:10.1016/j.avsg.2022.11.019
- Salisbury AC, Li H, Vilain KR, et al. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9(22):2343-2352. doi:10.1016/j.jcin.2016.08.036
- Pan T, Tian SY, Liu Z, Zhang T, Li C, Ji DH. Combination of RotarexⓇ S Rotational Atherothrombectomy and Drug-Coated Balloonangioplasty for Femoropopliteal Total In-Stent Occlusion. Ann Vasc Surg. 2022;80:213-222. doi:10.1016/j.avsg.2021.08.058
- Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol. 2019;73(2):214-237. doi:10.1016/j.jacc.2018.10.002
- Scheinert D, Schmidt A, Zeller T, et al. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther. 2016;23(3):409-416. doi:10.1177/1526602816644592
- Krankenberg H, Tübler T, Ingwersen M, et al. Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis: The Randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation. 2015;132(23):2230-2236. doi:10.1161/CIRCULATIONAHA.115.017364
- Baumann F, Fust J, Engelberger RP, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther. 2014;21(1):44-51. doi:10.1583/13-4486MR.1
Treten Sie unserer Community bei und überdenken Sie Ihre pAVK-Strategie
Verpassen Sie diese Gelegenheit nicht! Stimmen Sie dem Erhalt von Mitteilungen zu und genießen Sie exklusiven Zugang zu klinischen Daten, Sonderveranstaltungen und Inhalten, die speziell für Spezialisten für periphere arterielle Verschlusskrankheiten zusammengestellt wurden.